CryoPort (CYRX) Stock Forecast & Price Target

CryoPort is a global leader in temperature-controlled logistics for the increasingly important cell and gene therapy sector. With a strong portfolio of services and products, a growing customer base, and a focus on expanding its capabilities in a rapidly growing market, we believe that CryoPort is well-positioned for long-term success. Additionally, CryoPort's strong financial performance, with consistently strong revenue growth and improving margins, further supports our positive outlook on the stock. The company's focus on the high-growth cell and gene therapy market, coupled with its innovative logistics solutions and strong customer base, makes it a compelling investment opportunity. We believe that the company's stock has the potential for significant upside as more therapies are commercialized and revenue continues to grow.

CryoPort is expected to have strong revenue growth, but prudently remains conservative given geopolitical uncertainty, with a projected positive adjusted EBITDA in 2H26. Its revenue guidance of $192-196M in FY26, with strong commercial revenue, expects high single-digit growth. Risks to the target include slower pace of therapy approvals or competition in the cold-chain logistics market. However, with the company's clean first quarter and raised guidance, its price target is raised from $13 to $15 based on an EV/Sales multiple of 2.5x 2027E revenue estimate, showing potential for growth compared to peers.